ArticleClinical nuclear medicine2013
Variance of SUVs for FDG-PET/CT is greater in clinical practice than under ideal study settings.
Article in Clinical nuclear medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Repeatability of quantitativeEuropean journal of nuclear medicine and molecular imaging · 2018Pooled it
- QuantitativeRadiology · 2024Trial
- Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015Trial
- Comparative evaluation of quantitative analysis using two phantom-based software programs forRadiological physics and technology · 2025Article
- Visual and QuantitativeMolecular imaging and biology · 2025Article
- Comparative analysis of batch correction methods for FDG PET/CT using metabolic radiogenomic data of lung cancer patients.Scientific reports · 2023Article
- Precision of quantitative parameters ofQuantitative imaging in medicine and surgery · 2023Article
- Incidence of PSMA PET thyroid incidentaloma depends on analysis method and tracer.European radiology · 2023Article
- Article
- Value-assessment of computer-assisted navigation strategies during percutaneous needle placement.International journal of computer assisted radiology and surgery · 2022Article
- Method to determine the statistical technical variability of SUV metrics.EJNMMI physics · 2022Article
- Synergistic impact of motion and acquisition/reconstruction parameters onMedical physics · 2022Article
- The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients.Langenbeck's archives of surgery · 2022Article
- Influences on PET Quantification and Interpretation.Diagnostics (Basel, Switzerland) · 2022Review
- Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.Frontiers in bioengineering and biotechnology · 2022Article
- Quantitation of cancer treatment response by 2-[EJNMMI research · 2021Article
- Prevalence of incidental thyroid malignancy on routineEuropean journal of hybrid imaging · 2020Article
- Radiomics ofEuropean journal of nuclear medicine and molecular imaging · 2020Article
- The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.Radiology · 2020Article
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with [Molecular imaging and biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeMeasurement variance affects the clinical effectiveness of PET-based measurement as a semiquantitative imaging biomarker for cancer response in individual patients and for planning clinical trials. In this study, we measured test-retest reproducibility of SUV measurements under clinical practice conditions and recorded recognized deviations from protocol compliance.
methodsInstrument performance calibration, display, and analyses conformed to manufacture recommendations. Baseline clinical (18)F-FDG PET/CT examinations were performed and then repeated at 1 to 7 days. Intended scan initiation uptake period was to repeat the examinations at the same time for each study after injection of 12 mCi FDG tracer. Avidity of uptake was measured in 62 tumors in 21 patients as SUV for maximum voxel (SUV(max)) and for a mean of sampled tumor voxels (SUV(mean)).
resultsThe range of SUV(max) and SUV(mean) was 1.07 to 21.47 and 0.91 to 14.69, respectively. Intraclass correlation coefficient between log of SUV(max) and log of SUV(mean) was 0.93 (95% confidence interval [CI], 0.88-0.95) and 0.92 (95% CI, 0.87-0.95), respectively.Correlation analysis failed to show an effect on uptake period variation on SUV measurements between the 2 examinations, suggesting additional sources of noise.The threshold criteria for relative difference from baseline for the 95% CI were ± 49% or ± 44% for SUV(max) or SUV(mean), respectively.
conclusionsVariance of SUV for FDG-PET/CT in current clinical practice in a single institution was greater than expected when compared with benchmarks reported under stringent efficacy study settings. Under comparable clinical practice conditions, interpretation of changes in tumor avidity in individuals and assumptions in planning clinical trials may be affected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.